Basic & Clinical Cancer Research is a peer-reviewed, open-access journal that aims to publish the highest quality articles on all aspects of cancer research, including research findings of pathophysiology, prevention, diagnosis and treatment of cancers, and technical evaluations and serves as a discussion forum for cancer scientists.

 

This Journal is indexed in:

Dimensions

Directory of Open Access Journal (DOAJ)

EBSCO

Google Scholar

Index Copernicus

Islamic World Science Citation Center (ISC)

ProQuest   

Scientific Information Database (SID)

Ulrichsweb

             

 

Current Issue

Vol 13 No 3 (2021)

Original Articles

  • XML | PDF | downloads: 18 | views: 25 | pages: 175-186
    Background: Recently, it has been shown that, piRNAs as a new class of non-coding RNAs (ncRNAs), play crucial roles in germline development and carcinogenesis. Despite this, the study on the effects of piRNAs polymorphism (piR-SNP) on colorectal cancer (CRC) risk is scarce. We evaluate the impact of rs11776042 in piRNA 015551 on CRC initiation and development in the Iranian population. Matherials & METHODS: The association of novel polymorphisms rs11776042 in piRNA 015551 gene with CRC risk using a case-control study on the Iranian population was estimated. All subjects were evaluated by TETRA primer-Amplification refractory mutation system polymerase chain reaction (TP-ARMS- PCR assay) Results: The genotypes frequency was 27%, 68% and 0.05% for C/C, C/T and T/T in controls and 31%, 65% and 0.04% in CRC patients respectively. The frequency of the C allele was 63% in patients versus 61% in controls and, T allele frequency was 37% in patients versus 39% in controls. Conclusion: No significant difference was found in genotype and allele frequencies between the cases and controls for rs11776042 polymorphism in piRNA 015551 in our population.  
  • XML | PDF | downloads: 6 | views: 11 | pages: 187-192
    Background: In March 2020, the World Health Organization declared the novel COVID-19 infection a pandemic. Among high-risk patients infected by the virus, upper gastrointestinal cancer patients similar to other immunosuppressed patients are vulnerable to develop more severe infections. Most of the routine activities of medical centers, especially cancer surgery centers around the world, are affected by this epidemic. Thus, some modifications are needed to adjust international protocols to deal with upper gastrointestinal cancers in all the world. Methods: The headings of upper gastrointestinal cancer management protocols have been discussed among the university-affiliated professors in different disciplines involved in upper gastrointestinal cancer management. The discussions were done through an interactive application (WhatsApp & Telegram) in which participants considered the headlines and the latest news about COVID-19. Under each heading, we provide the consensus of all members in the related disciplines. Recommendations and Conclusion: In each specialty, all members agreed to choose minimal intervention. The members know that some recommendations may interfere with the routine best-practice recommendations and decrease the quality measures in the patient's outcome. Therefore, these recommendations are valid just in epidemic COVID-19 situation. According to the consensus of cancer surgery professors in several cancer surgery centers, gastric cancer  with T1, T2 and T3 but N0 should be upfront operated but in T3 or N1 or more, the surgery after six courses of chemotherapy should be postponed until the end of the COVID-19  Epidemic and in this phase no diagnostic laparoscopy will be performed , but in the esophageal cancer, T1,T2 and N0 should be upfront operated but T3, T4 and N1 or more, a PET-CT scan will be performed. In the status of high uptake and severe dysphagia, the stent placement is reasonable but in low uptake without any dysphagia, only conservation is our suggestion. Keywords: Upper Gastrointestinal Cancers; COVID-19; Outbreak; Cancer Surgery Centers; Consensus

Reviews

  • XML | PDF | downloads: 18 | views: 19 | pages: 156-174
    Progress in cancer stem cells has opened up a new window to develop better cancer treatment methods. Several pre-clinical and clinical trial studies use CSCs targeting via surface markers method and inhibition of stem cell pathway to eradicate cancer. Albite, some important question was unclear about CSCs origin and molecular mechanism of self-renewal, the structure of CSCs markers and so on, but the eradication of these cells eliminate cancer. In this review, we have argued about the CSC surface markers on different cancers, the mechanisms of action, and therapeutic procedures related to the cancer biomarkers. Then, we have discussed the challenges of these therapies.
View All Issues